Skip to main content
SpringerLink
Log in

Immunohistochemistry

  • Chapter
  • First Online:
Diffuse Malignant Mesothelioma

  • 962 Accesses

Abstract

Immunohistochemistry is important for both distinguishing benign mesothelial proliferations from diffuse malignant mesothelioma (DMM) and for differentiating DMM from metastatic malignancies involving the pleura. Histologic diagnosis alone is often impossible. The exact makeup of immunohistochemical panels used for DMM diagnosis depends on the differential diagnosis and on the antibodies available in a given laboratory. Distinguishing reactive mesothelial cell hyperplasia from DMM is a significant challenge for which the role of immunohistochemistry is limited; however, it is extremely helpful when examining tissue for invasion to the stroma, fat, or lung parenchyma. The role of immunohistochemistry is also relatively limited in sarcomatous DMM diagnosis because mesothelial markers are less often positive.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac LR, Churg A, Dacic S, Fraire A, Galateau-Salle F, Gibbs A, Gown A, Hammar S, Litzky L, Marchevsky AM, Nicholson AG, Roggli V, Travis WD, Wick M. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2013;137(5):647–67.

    Article  PubMed  Google Scholar 

  2. Churg A, Galateau-Salle F. The separation of benign and malignant mesothelial proliferations. Arch Pathol Lab Med. 2012;136(10):1217–26.

    Article  PubMed  Google Scholar 

  3. Shi M, Fraire AE, Chu P, Comejo K, Woda BA, Dresser K, Rock KL, Jiang Z. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol. 2011;35(6):878–82.

    Article  PubMed  Google Scholar 

  4. Lee AF, Gown AM, Churg A. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations. Am J Surg Pathol. 2013;37(3):421–6.

    Article  PubMed  Google Scholar 

  5. Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, Suzuki K, Asamura H, Tsuchiya R, Matsuno Y. Immunohistochemical detection of GLUT-1can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20(2):215–20.

    Article  CAS  PubMed  Google Scholar 

  6. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium: a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003;43(3):231–8.

    Article  CAS  PubMed  Google Scholar 

  7. Klebe S, Brownlee NA, Mahar A, Burchette JL, Sporn TA, Vollmer RT, Roggli VL. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol. 2010;23(3):470–9.

    Article  PubMed  Google Scholar 

  8. Husain AN, Colby TV, Ordonez NG, Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, Gown AM, Hammer SP, Litzky LA, Roggli VL, Travis WD, Wick MR. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2009;133(8):1317–31.

    PubMed  Google Scholar 

  9. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003;27:1031–51.

    Article  PubMed  Google Scholar 

  10. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol. 2000;24:598–6.

    Article  CAS  PubMed  Google Scholar 

  11. Ordonez NG. Napsin A expression in lung and kidney neoplasia: a review and update. Adv Anat Pathol. 2012;19:66–73.

    Article  CAS  PubMed  Google Scholar 

  12. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006;19:417–28.

    Article  PubMed  Google Scholar 

  13. Ordonez NG. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. Hum Pathol. 2013;44(1):1–19.

    Article  CAS  PubMed  Google Scholar 

  14. Duhig EE, Kalpakos L, Yang IA, Clarke BE. Mesothelial markers in high-grade breast carcinoma. Histopathology. 2011;59:957–64.

    Article  PubMed  Google Scholar 

  15. Powell G, Roche H, Roche WR. Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma. Histopathology. 2011;59:950–6.

    Article  PubMed  Google Scholar 

  16. Kaimaktchiev V, Terracciano L, Tornillo L, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol. 2004;17:1392–9.

    Article  CAS  PubMed  Google Scholar 

  17. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-40, a novel mesothelial maker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005;18(1):105–10.

    Article  CAS  PubMed  Google Scholar 

  18. Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol. 2005;36(4):372–80.

    Article  CAS  PubMed  Google Scholar 

  19. Ordonez NG. Value of calretinin immunostainingin diagnostic pathology: a review and update. Appl Immunohistochem Mol Morphol. 2014;22(6):401–15.

    Article  CAS  PubMed  Google Scholar 

  20. Mittenen, M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelinin lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol. 2003;27:150–58.

    Article  Google Scholar 

  21. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006;19:417–28.

    Article  PubMed  Google Scholar 

  22. Lugli A, Forster Y, Haas P, Nocito A, Bucher C, Bissig H, Mirlacher M, Storz M, Mihatsch MJ, Sauter G. Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. Human Pathol. 2003;34:994–1000.

    Article  CAS  Google Scholar 

  23. Ordonez NG. Podoplanin: a novel diagnostic immunohistochemical marker. Adv Anat Pathol. 2006;13:83–8.

    Article  CAS  PubMed  Google Scholar 

  24. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005;18:105–10.

    Article  CAS  PubMed  Google Scholar 

  25. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol 2004;35:697–10.

    Article  CAS  PubMed  Google Scholar 

  26. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418–28.

    Article  PubMed  Google Scholar 

  27. Amatya VJ, Takeshima Y, Kohono H, Kushitani K, Yamada T, Morimoto C, Inai K. Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Histopathology. 2009;55(1):10–19.

    Article  PubMed  Google Scholar 

  28. Winter MJ, Nagtegaal ID, van Krieken JHJM, Litvinov SV. The epithelial cell adhesion molecule (ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol. 2003;163:2139–48.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Ordonez NG. Value of claudin-4 immunostaining in the diagnosis of mesothelioma. Am J Clin Pathol. 2013;139(5):611–19.

    Article  CAS  PubMed  Google Scholar 

  30. Ordonez NG. Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma. Mod Pathol. 2013;26(8):1132–43.

    Article  CAS  PubMed  Google Scholar 

  31. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol. 2007;127:103–13.

    Article  CAS  PubMed  Google Scholar 

  32. Takeda Y, Tsuta K, Shibuki Y, et al. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors. Arch Pathol Lab Med. 2008;132:239–43.

    PubMed  Google Scholar 

  33. Sasaki E, Tsunoda N, Hatanaka Y, Mori N, Iwata H, Yatabe Y. Breast specific expression of MGB1/mammoglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol. 2007;20:208–14.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Texas Medical Branch, 301 University Blvd., 2.190JSA, 77555, Galveston, TX, USA

    Nahal Boroumand

Authors
  1. Nahal Boroumand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nahal Boroumand .

Editor information

Editors and Affiliations

  1. Department of Pathology and Laboratory Medicine, The University of Texas Medical Branch, Galveston, Texas, USA

    Timothy Craig Allen

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Boroumand, N. (2015). Immunohistochemistry. In: Allen, T. (eds) Diffuse Malignant Mesothelioma. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2374-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2374-8_5

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-2373-1

  • Online ISBN: 978-1-4939-2374-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation